BTLA-HVEM Interaction Network
(https://doi.org/10.1016/j.ejmech.2024.116231)
| Application | Focus |
Representative Programs |
Core Mechanisms |
|---|---|---|---|
|
Tumor Immunotherapy |
Solid tumors & hematologic malignancies |
1. BTLA blockade: Tifcemalimab (anti-BTLA mAb) 2. Dual blockade: Tifcemalimab + Toripalimab (anti-PD-1) |
1. Restore T/NK cell cytotoxicity 2. Reverse T-cell exhaustion 3. Enhance immune cell infiltration into the TME |
|
Autoimmune Diseases |
Inflammatory diseases, atopic dermatitis, Sjögren’s syndrome, SLE, psoriasis |
ANB032 (BTLA agonist) |
1. Suppress autoreactive T-cell activation 2. Reduce excessive inflammatory responses |
|
Neuroimmune Diseases |
Multiple sclerosis, neuromyelitis optica |
VTC-890 (LIGHT/TL1A bispecific mAb) + Interferon β (investigational) |
1. Reduce demyelination 2. Restore immune homeostasis in the CNS |
The purity of Human LIGHT Protein, Fc Tag (Cat. No. LIT-H5269) is more than 95% and the molecular weight of this protein is around 180-200 kDa verified by SEC-MALS.
Request Report
Loaded Human BTLA (31-150), His Tag (Cat. No. BTA-H52H3) on NTA Biosensor, can bind Human HVEM, Mouse IgG2a Fc Tag, low endotoxin with an affinity constant of 20.8 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Request Protocol
Human LIGHT Protein, His Tag (Cat. No. LIT-H5242) induced cytotoxicity in HT-29 cells. The ED50 for this effect is 1.11-3.87 ng/mL (Routinely tested).
Request Protocol
Expression analysis of human HVEM on Human HVEM (Luc) HEK293 Reporter Cell by FACS.Cell surface staining was performed on Human HVEM (Luc) HEK293 Reporter Cell (Cat. No. CHEK-ATF105) or negative control cell using PE-labeled anti-human HVEM antibody
Request Protocol
Inhibition of human BTLA overexpressing on CHO cells induced reporter activity by anti-human BTLA antibody.This reporter cell was incubated with serial dilutions of antibodies in the presence of CHO/Human BTLA Stable Cell Line (Cat. No. SCCHO-ATP110). The EC50 of anti-human BTLA neutralizing antibody is approximately 0.212 μg/mL.
Request Protocol
Passage stability analysis by Signaling Bioassay. The continuously growing Human HVEM (Luc) HEK293 Reporter Cell (Cat. No. CHEK-ATF105) was incubated with CHO/Human BTLA Stable Cell Line (Cat. No. SCCHO-ATP110). The human BTLA-overexpressing CHO cells stimulated response demonstrates passage stabilization (fold induction) across passage 7-25.
Request Protocol
Passage stability analysis of receptor expression by FACS. Flow cytometry surface staining of human BTLA on CHO/Human BTLA Stable Cell Line (Cat. No. SCCHO-ATP110) demonstrates consistent mean fluorescent intensity across passage 3-20.
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Quisovalimab | CERC-002; AEVI-002; MDGN-002; SAR-252067; AVTX-002 | Phase 2 Clinical | La Jolla Pharmaceutical Company, Kyowa Hakko Kirin Co Ltd | Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Colitis, Ulcerative; Asthma; Acute Lung Injury; Crohn Disease | Details |
| HFB-200603 | HFB-200603 | Phase 1 Clinical | HiFiBiO Therapeutics | Stomach Neoplasms; Carcinoma, Renal Cell; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| HFB200604 AID | HFB-200604-AID; HFB200604; HFB-200604; HFB200604 AID | Phase 1 Clinical | HiFiBiO Therapeutics | Autoimmune Diseases; Inflammation | Details |
| Venanprubart | LY-3361237 | Phase 1 Clinical | Sanford-Burnham Medical Research Institute, Eli Lilly And Company | Sjogren's Syndrome; Lupus Erythematosus, Systemic; Psoriasis | Details |
| ANB-032 | ANB-032 | Phase 1 Clinical | Anaptysbio Inc | Inflammation; Dermatitis, Atopic; Eczema | Details |
| MB-272 | MB272; GS-0272 | Phase 1 Clinical | University Of Oxford, MiroBio Ltd | Autoimmune Diseases; Arthritis, Rheumatoid | Details |
| Tifcemalimab | JS-004; TAB-004 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Hodgkin Disease; Neoplasms; Nasopharyngeal Carcinoma; Lymphoma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma | Details |
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email:order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland